Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07516132 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
A Phase 3 study, sponsored by Ocular Therapeutix.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 850
- Enrollment target
NCT07516132 is a Phase 3 study that is actively recruiting participants, run by Ocular Therapeutix. The registered enrollment target is 850 participants.
The verdict
NCT07516132, a Phase 3 study, is actively recruiting participants, sponsored by Ocular Therapeutix.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 850 participants
- Enrollment target
Study Summary
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Interventions
- DRUG OTX-TKI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07516132
The ClinicalTrials.gov registry entry for NCT07516132 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTX-TKI is the first listed.
NCT07516132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07516132 about?
NCT07516132 is a clinical study titled "Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study". Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
What is the current status of trial NCT07516132?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2026-04-27. Estimated completion is 2030-08-01.
What interventions are being tested in trial NCT07516132?
The interventions under investigation include: OTX-TKI (DRUG).
Who is sponsoring clinical trial NCT07516132?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.